Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Michael Tanen"'
Autor:
Julie A. Stone, Mark S. Forman, Marissa F. Dockendorf, John Palcza, Lei Ma, Michael Tanen, Marianne van Vugt, Matthew D. Troyer, Huub Jan Kleijn, Kazuko Masuo, Peter Hodsman, Jack Tseng, K Chris Min
Publikováno v:
Clinical Pharmacology & Therapeutics. 105:1234-1243
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of β-amyloid (Aβ) peptides and is considered a potential treatment target for Alzheimer's disease (AD). To support Japan's participation in the global clinic
Autor:
Philip Scheltens, Christy Weiss, Jackie Surls, Arie Struyk, Cyrille Sur, Kimberly Wilson, Julie Stromswold, Mary J. Savage, Johan Luthman, Stephanie R. Rainey-Smith, David Darby, Sigrid Botne Sando, Omar F Laterza, James R. Burke, Arturo Cowes, Linda R. White, Geir Bråthen, Eileen Sagini, Michael Tanen, Michele M. Bush, Amy Altman, Charlotte E. Teunissen, Michael F. Egan, Yi Mo, Ganga DeSilva, Daniel J. Holder, S. Lance Macaulay
Publikováno v:
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 6, 201-209. Elsevier BV
Mo, Y, Stromswold, J, Wilson, K, Holder, D, Sur, C, Laterza, O, Savage, M J, Struyk, A, Scheltens, P, Teunissen, C E, Burke, J, Macaulay, S L, Bråthen, G, Sando, S B, White, L R, Weiss, C, Cowes, A, Bush, M M, DeSilva, G, Darby, D G, Rainey-Smith, S R, Surls, J, Sagini, E, Tanen, M, Altman, A, Luthman, J & Egan, M F 2017, ' A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging ', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 6, pp. 201-209 . https://doi.org/10.1016/j.dadm.2017.02.004
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 6, 201-209. Elsevier BV
Mo, Y, Stromswold, J, Wilson, K, Holder, D, Sur, C, Laterza, O, Savage, M J, Struyk, A, Scheltens, P, Teunissen, C E, Burke, J, Macaulay, S L, Bråthen, G, Sando, S B, White, L R, Weiss, C, Cowes, A, Bush, M M, DeSilva, G, Darby, D G, Rainey-Smith, S R, Surls, J, Sagini, E, Tanen, M, Altman, A, Luthman, J & Egan, M F 2017, ' A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging ', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 6, pp. 201-209 . https://doi.org/10.1016/j.dadm.2017.02.004
Introduction Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzhei
Autor:
Frank D. Sistare, William Boshoven, Brian R. Lane, Warren E. Glaab, Stephen K. Babitz, Allen Wong, Maureen Gebben, Pam Grady, Susan Engerman, Sabrina L. Noyes, Katerina Vlasakova, Cindy Zimmerman, Michael Tanen
Publikováno v:
European urology focus. 6(6)
Background Partial nephrectomy (PN) is the gold standard for the treatment of small renal masses. Urinary biomarkers (UBMs) may serve as early indicators of acute kidney injury (AKI) following PN. Objective To evaluate the timing, specificity, and se
Autor:
Daniel J. Holder, Jeffrey L. Seeburger, C Joachim, Mary J. Savage, A. David Smith, Marc Combrinck, Vijay Modur, Karen Snyder, William Z. Potter, Michael Tanen, Derek L Chappell, Adam J. Simon, Omar F Laterza, Mary Flynn, Gordon K. Wilcock, Aimee Dallob
Publikováno v:
Journal of Alzheimer's Disease. 44:525-539
Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of Alzheimer's disease (AD). Combined Aβ42 and t-tau distinguishes AD from healthy controls with a sensitivity and specificity (sens/spec) near 89% across studies. This
Autor:
Christopher J. Winrow, Mary J. Savage, Kyeongmi Cheon, Mark S. Forman, Michael F. Egan, Matthew E. Kennedy, Juliya Kalinina, Michael Tanen, Julie A. Stone
Publikováno v:
Alzheimer's & Dementia. 13
Publikováno v:
The AAPS Journal. 16:914-924
Over the last few years, numerous ligand binding assay technologies that utilize real-time measurement have been introduced; however, an assemblage and evaluation of these technologies has not previously been published. Herein, we describe six emergi
Autor:
Huub Jan Kleijn, Jared N. Cumming, Xia Chen, John Palcza, Britta A. Mattson, Michael Tanen, Julie A. Stone, Wei Li, Eric M. Parker, Hong Mei, Reshma Kuvelkar, Stanford Jhee, Robert A. Hodgson, Jack Tseng, Lynn A. Hyde, Andrew Stamford, Matthew E. Kennedy, Kathleen Cox, Michael F. Egan, Larry Ereshefsky, Mark S. Forman, Marissa F. Dockendorf, Jack D. Scott, Matthew D. Troyer
Publikováno v:
Science translational medicine. 8(363)
β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of Aβ, and BACE1 inhibition
Autor:
Eileen Sagini, Michael Tanen, Jacqueline Surls, Ganga DeSilva, Christy Weiss, Michele M. Bush, Amy Altman, Jeremy Bridge-Cook, Arturo Cowes, Omar F Laterza
Publikováno v:
Alzheimer's & Dementia. 11
Autor:
Veronica M. Rivas, Nicoletta Morelli, Ingrid M C Kamerling, Michael Tanen, Rob Zuiker, J. Diderik Boot, Robin Mogg, Marcella Ruddy, Kristien Van Dyck, Inge De Lepeleire, Zuzana Diamant
Publikováno v:
European Clinical Respiratory Journal
European Clinical Respiratory Journal; Vol 2 (2015)
European clinical respiratory journal, 2(1):28319. Taylor & Francis Group
European Clinical Respiratory Journal; Vol 2 (2015)
European clinical respiratory journal, 2(1):28319. Taylor & Francis Group
Background : Allergen-induced late airway response offers important pharmacodynamic targets, including T helper 2 (TH2) biomarkers. However, detection of inflammatory markers has been limited in dithiothreitol-processed sputum. Objectives : To test w
Autor:
Mark Kipnes, Amy Qiu Wang, Deborah Hilliard, Kenneth C. Lasseter, John A. Wagner, Karen Snyder, Keith Gottesdiener, Wesley Tanaka, Bruno Dietrich, Jens J. Holst, Peng Zhao, Andreas Schrodter, Bart Keymeulen, Catherine Stevens, Carolyn F. Deacon, Kristien Van Dyck, Inge De Lepeleire, Caroline Cilissen, Arthur J. Bergman, Gary A. Herman, Wei Zeng, Marina De Smet, George Golor, Bingming Yi, Michael J. Davies, Paul Kotey, Michael Tanen
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:4612-4619
In response to a meal, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are released and modulate glycemic control. Normally these incretins are rapidly degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors ar